Novartis India's New Chief Has A Full Plate
Ex-AstraZeneca executive Sanjay Murdeshwar will lead Novartis in India. The incoming head faces multiple challenges including balancing profitable growth and access in a largely self-pay market.
You may also be interested in...
Novartis India chief outlines how the company is navigating the challenging business environment amid the coronavirus pandemic, including for its for-profit social business. Digital solutions are a key part of these efforts and the executive offers advice for those struggling to balance the work-life mix in these testing times.
Top-level personnel movement continues at pharma firms in India, with Cipla now appointing an ex-Amneal executive as its Chief Scientific Officer, while Abbott has effected a rejig at the helm.
Novartis is planning to launch Aimovig in India after the migraine therapy was endorsed by an expert panel, but all eyes will be on pricing and how the company’s recent dispute with partner Amgen plays out.